“…However, we have developed a conformationally-biased, responseselective, decapeptide agonist of C5a, C5a 65-74 Y65,F67,P69, P71,D-Ala-73 (YSFKPMPLaR or EP54) that retains C5a-like immune stimulatory properties at the expense of C5a-like inflammatory properties via the engagement of neutrophils [10][11][12][13]. This bio-selectivity results from the unique conformational features expressed by EP54, which are well accommodated by C5a receptors (C5aR) expressed on antigen presenting cells such as DCs and macrophages, but not by C5aRs on neutrophils [14,15]. These conformational features also render EP54 stable to proteolysis by serum carboxypeptidases [16].…”